<p>美国银行（Bank of America Corp DE）在最近向证券交易委员会提交的文件中表示，在第四季度减少了对 Rocket Pharmaceuticals, Inc.（NASDAQ:RCKT - 免费报告）的持股比例，降幅为 44.8%。该公司在出售了 181,848 股后，现持有 224,311 股生物技术公司的股票。截至最近的 SEC 文件，美国银行持有 Rocket Pharmaceuticals 0.25% 的股份，价值 2,820,000 美元。</p>
<p>获取 <strong>Rocket Pharmaceuticals</strong> 的提醒：</p>
<ul>
<li>3 只准备大幅上涨的小型股</li>
</ul>
<p>其他机构投资者和对冲基金也调整了对该公司的持股。Jennison Associates LLC 在第四季度将其在 Rocket Pharmaceuticals 的股份增加了 72.6%。Jennison Associates LLC 现在持有 70,304 股生物技术公司的股票，价值 884,000 美元，此前在上个季度购买了 29,564 股。Sovran Advisors LLC 在第四季度购买了 Rocket Pharmaceuticals 的新头寸，价值约为 1,895,000 美元。Raymond James Financial Inc.在第四季度购买了 Rocket Pharmaceuticals 的新头寸，价值约为 285,000 美元。Strategic Financial Concepts LLC 在第四季度购买了 Rocket Pharmaceuticals 的新股份，价值约为 141,000 美元。最后，Charles Schwab Investment Management Inc.在第四季度将其在 Rocket Pharmaceuticals 的股份增加了 15.1%。Charles Schwab Investment Management Inc.现在持有 656,090 股生物技术公司的股票，价值 8,247,000 美元，此前在上个季度购买了 86,276 股。机构投资者和对冲基金持有该公司 98.39% 的股份。</p>
<h2>Rocket Pharmaceuticals 股价下跌 5.3%</h2>
<p>RCKT 的股票在周五开盘价为 2.48 美元。该公司的债务与股本比率为 0.06，流动比率为 6.05，速动比率为 6.05。该公司的 50 日简单移动平均为 6.20 美元，200 日简单移动平均为 9.45 美元。Rocket Pharmaceuticals, Inc.的 1 年最低价为 2.19 美元，1 年最高价为 26.98 美元。该股票的市值为 2.6483 亿美元，市盈率为-0.90，贝塔值为 1.02。</p>
<p>Rocket Pharmaceuticals（NASDAQ:RCKT - 获取免费报告）最近于 5 月 13 日发布了其财报。该生物技术公司报告第四季度每股收益（EPS）为（$0.56），超出市场共识预期的（$0.58）$0.02。在去年同期，该公司每股收益为（$0.66）。股票分析师预测 Rocket Pharmaceuticals, Inc.在当前财政年度将发布-2.83 的每股收益。</p>
<h2>内部交易活动</h2>
<p>在相关消息中，首席执行官 Gaurav Shah 于 4 月 10 日星期四购买了 20,000 股公司的股票。该股票的平均购买价格为每股 5.08 美元，总价值为 101,600.00 美元。交易完成后，首席执行官现在持有 792,680 股公司的股票，价值约为 4,026,814.40 美元。这笔交易代表了其持股比例的 2.59% 的增加。该收购在 SEC 的文件中披露，可以通过此链接访问。此外，首席财务官 Aaron Ondrey 于 4 月 4 日星期五出售了 7,489 股公司的股票。该股票的平均售价为 5.29 美元，总交易额为 39,616.81 美元。交易完成后，首席财务官现在直接持有 129,650 股公司的股票，价值 685,848.50 美元。这笔交易是其持股比例的 5.46% 的减少。该销售的披露信息可以在这里找到。公司内部人士持有该公司 24.76% 的股份。</p>
<h2>分析师设定新目标价</h2>
<p>多家研究公司最近对 RCKT 发布了报告。BMO 资本市场将 Rocket Pharmaceuticals 的目标价从 30.00 美元下调至 8.00 美元，并在周三的研究报告中对该公司给予了 “跑赢大盘” 的评级。Wedbush 重申了 “跑赢大盘” 的评级，并在 5 月 16 日星期五的研究报告中对 Rocket Pharmaceuticals 的股票设定了 32.00 美元的目标价。高盛集团在周三的报告中将 Rocket Pharmaceuticals 的评级从 “中性” 下调至 “卖出”。Canaccord Genuity Group 在 5 月 12 日星期一的报告中将 Rocket Pharmaceuticals 的目标价从 36.00 美元下调至 34.00 美元，并对该股票给予了 “买入” 评级。最后，摩根士丹利在周三的研究报告中重申了 “持平” 的评级，并对 Rocket Pharmaceuticals 的股票设定了 7.00 美元的目标价。一位投资分析师对该股票给予了 “卖出” 评级，八位分析师给予了 “持有” 评级，九位分析师对该公司的股票给予了 “买入” 评级。根据 MarketBeat 的数据，Rocket Pharmaceuticals 目前的共识评级为 “持有”，共识目标价为 21.21 美元。</p>
<p><strong>获取我们最新的 RCKT 股票分析</strong></p>
<h2>关于 Rocket Pharmaceuticals</h2>
<p>（免费报告）</p>
<p>Rocket Pharmaceuticals, Inc 及其子公司作为一家晚期生物技术公司，专注于开发针对罕见和严重疾病的基因疗法。它有三个临床阶段的外源性慢病毒载体项目，分别针对范可尼贫血（Fanconi anemia）、白细胞粘附缺陷-I（leukocyte adhesion deficiency-I）和丙酮酸激酶缺乏症（pyruvate kinase deficiency）。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 Rocket Pharmaceuticals</li>
<li>如何投资蓝筹股</li>
<li>接近 52 周低点，这 3 只中型股值得关注</li>
<li>外汇是什么，如何运作？</li>
<li>3 个被忽视的股息投资机会，适合波动时期</li>
<li>TSX 风险投资交易所（前身为加拿大风险投资交易所）</li>
<li>AXON：竞争加剧，摩托罗拉以 44 亿美元收购</li>
</ul>
<p><strong>想知道其他对 RCKT 持有仓位的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - 免费报告) 的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkNLVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkNLVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Rocket Pharmaceuticals 吗？</h2>
<p>在考虑 Rocket Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Rocket Pharmaceuticals 并不在名单上。</p>
<p>虽然 Rocket Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

美国银行

Rocket制药

<p>美国银行（Bank of America Corp DE）在第四季度减少了对 Rocket Pharmaceuticals, Inc.（NASDAQ:RCKT）44.8% 的持股，目前持有 224,311 股，价值 282 万美元。其他机构投资者也调整了他们的持仓。RCKT 的股价下跌 5.3%，至 2.48 美元，市值为 2.6483 亿美元。该公司报告的季度每股收益为（0.56 美元），超出预期。分析师的目标价格各不相同，BMO 将其下调至 8.00 美元，而 Wedbush 维持在 32.00 美元。内部交易方面，首席执行官 Gaurav Shah 购买了 20,000 股</p>

<p>Bank of America Corp DE lessened its stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 44.8% in the 4th quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The firm owned 224,311 shares of the biotechnology company's stock after selling 181,848 shares during the quarter. Bank of America Corp DE owned 0.25% of Rocket Pharmaceuticals worth $2,820,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>美国银行（Bank of America Corp DE）在最近向证券交易委员会提交的文件中表示，在第四季度减少了对 Rocket Pharmaceuticals, Inc.（NASDAQ:RCKT - 免费报告）的持股比例，降幅为 44.8%。该公司在出售了 181,848 股后，现持有 224,311 股生物技术公司的股票。截至最近的 SEC 文件，美国银行持有 Rocket Pharmaceuticals 0.25% 的股份，价值 2,820,000 美元。</p>
</div><p>Get <strong>Rocket Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Rocket Pharmaceuticals</strong> 的提醒：</p>
</div><ul>
<li>3 Small-Cap Stocks That Are Ready to Rocket Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只准备大幅上涨的小型股</li>
</ul>
</div><p>Other institutional investors and hedge funds have also modified their holdings of the company. Jennison Associates LLC increased its stake in shares of Rocket Pharmaceuticals by 72.6% in the 4th quarter. Jennison Associates LLC now owns 70,304 shares of the biotechnology company's stock valued at $884,000 after purchasing an additional 29,564 shares in the last quarter. Sovran Advisors LLC purchased a new position in shares of Rocket Pharmaceuticals in the 4th quarter valued at about $1,895,000. Raymond James Financial Inc. purchased a new position in shares of Rocket Pharmaceuticals in the 4th quarter valued at about $285,000. Strategic Financial Concepts LLC purchased a new stake in Rocket Pharmaceuticals during the 4th quarter worth approximately $141,000. Finally, Charles Schwab Investment Management Inc. increased its stake in Rocket Pharmaceuticals by 15.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 656,090 shares of the biotechnology company's stock worth $8,247,000 after buying an additional 86,276 shares in the last quarter. Institutional investors and hedge funds own 98.39% of the company's stock.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金也调整了对该公司的持股。Jennison Associates LLC 在第四季度将其在 Rocket Pharmaceuticals 的股份增加了 72.6%。Jennison Associates LLC 现在持有 70,304 股生物技术公司的股票，价值 884,000 美元，此前在上个季度购买了 29,564 股。Sovran Advisors LLC 在第四季度购买了 Rocket Pharmaceuticals 的新头寸，价值约为 1,895,000 美元。Raymond James Financial Inc.在第四季度购买了 Rocket Pharmaceuticals 的新头寸，价值约为 285,000 美元。Strategic Financial Concepts LLC 在第四季度购买了 Rocket Pharmaceuticals 的新股份，价值约为 141,000 美元。最后，Charles Schwab Investment Management Inc.在第四季度将其在 Rocket Pharmaceuticals 的股份增加了 15.1%。Charles Schwab Investment Management Inc.现在持有 656,090 股生物技术公司的股票，价值 8,247,000 美元，此前在上个季度购买了 86,276 股。机构投资者和对冲基金持有该公司 98.39% 的股份。</p>
</div><h2>Rocket Pharmaceuticals Trading Down 5.3%</h2>
<div class="lb-trans"><h2>Rocket Pharmaceuticals 股价下跌 5.3%</h2>
</div><p>Shares of RCKT opened at $2.48 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.05 and a quick ratio of 6.05. The firm has a 50 day simple moving average of $6.20 and a 200-day simple moving average of $9.45. Rocket Pharmaceuticals, Inc. has a 1-year low of $2.19 and a 1-year high of $26.98. The stock has a market cap of $264.83 million, a price-to-earnings ratio of -0.90 and a beta of 1.02.</p>
<div class="lb-trans"><p>RCKT 的股票在周五开盘价为 2.48 美元。该公司的债务与股本比率为 0.06，流动比率为 6.05，速动比率为 6.05。该公司的 50 日简单移动平均为 6.20 美元，200 日简单移动平均为 9.45 美元。Rocket Pharmaceuticals, Inc.的 1 年最低价为 2.19 美元，1 年最高价为 26.98 美元。该股票的市值为 2.6483 亿美元，市盈率为-0.90，贝塔值为 1.02。</p>
</div><p>Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last released its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.02. During the same quarter in the previous year, the firm earned ($0.66) earnings per share. Equities analysts forecast that Rocket Pharmaceuticals, Inc. will post -2.83 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Rocket Pharmaceuticals（NASDAQ:RCKT - 获取免费报告）最近于 5 月 13 日发布了其财报。该生物技术公司报告第四季度每股收益（EPS）为（$0.56），超出市场共识预期的（$0.58）$0.02。在去年同期，该公司每股收益为（$0.66）。股票分析师预测 Rocket Pharmaceuticals, Inc.在当前财政年度将发布-2.83 的每股收益。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In related news, CEO Gaurav Shah bought 20,000 shares of the company's stock in a transaction dated Thursday, April 10th. The stock was bought at an average price of $5.08 per share, with a total value of $101,600.00. Following the transaction, the chief executive officer now owns 792,680 shares of the company's stock, valued at approximately $4,026,814.40. This trade represents a 2.59% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Aaron Ondrey sold 7,489 shares of the business's stock in a transaction dated Friday, April 4th. The stock was sold at an average price of $5.29, for a total transaction of $39,616.81. Following the completion of the sale, the chief financial officer now directly owns 129,650 shares of the company's stock, valued at $685,848.50. The trade was a 5.46% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 24.76% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席执行官 Gaurav Shah 于 4 月 10 日星期四购买了 20,000 股公司的股票。该股票的平均购买价格为每股 5.08 美元，总价值为 101,600.00 美元。交易完成后，首席执行官现在持有 792,680 股公司的股票，价值约为 4,026,814.40 美元。这笔交易代表了其持股比例的 2.59% 的增加。该收购在 SEC 的文件中披露，可以通过此链接访问。此外，首席财务官 Aaron Ondrey 于 4 月 4 日星期五出售了 7,489 股公司的股票。该股票的平均售价为 5.29 美元，总交易额为 39,616.81 美元。交易完成后，首席财务官现在直接持有 129,650 股公司的股票，价值 685,848.50 美元。这笔交易是其持股比例的 5.46% 的减少。该销售的披露信息可以在这里找到。公司内部人士持有该公司 24.76% 的股份。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of research firms have recently issued reports on RCKT. BMO Capital Markets dropped their price target on Rocket Pharmaceuticals from $30.00 to $8.00 and set an &#34;outperform&#34; rating for the company in a research report on Wednesday. Wedbush reiterated an &#34;outperform&#34; rating and issued a $32.00 price objective on shares of Rocket Pharmaceuticals in a research note on Friday, May 16th. The Goldman Sachs Group lowered Rocket Pharmaceuticals from a &#34;neutral&#34; rating to a &#34;sell&#34; rating in a report on Wednesday. Canaccord Genuity Group dropped their price objective on Rocket Pharmaceuticals from $36.00 to $34.00 and set a &#34;buy&#34; rating on the stock in a report on Monday, May 12th. Finally, Morgan Stanley reiterated an &#34;equal weight&#34; rating and set a $7.00 target price on shares of Rocket Pharmaceuticals in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat, Rocket Pharmaceuticals currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $21.21.</p>
<div class="lb-trans"><p>多家研究公司最近对 RCKT 发布了报告。BMO 资本市场将 Rocket Pharmaceuticals 的目标价从 30.00 美元下调至 8.00 美元，并在周三的研究报告中对该公司给予了 “跑赢大盘” 的评级。Wedbush 重申了 “跑赢大盘” 的评级，并在 5 月 16 日星期五的研究报告中对 Rocket Pharmaceuticals 的股票设定了 32.00 美元的目标价。高盛集团在周三的报告中将 Rocket Pharmaceuticals 的评级从 “中性” 下调至 “卖出”。Canaccord Genuity Group 在 5 月 12 日星期一的报告中将 Rocket Pharmaceuticals 的目标价从 36.00 美元下调至 34.00 美元，并对该股票给予了 “买入” 评级。最后，摩根士丹利在周三的研究报告中重申了 “持平” 的评级，并对 Rocket Pharmaceuticals 的股票设定了 7.00 美元的目标价。一位投资分析师对该股票给予了 “卖出” 评级，八位分析师给予了 “持有” 评级，九位分析师对该公司的股票给予了 “买入” 评级。根据 MarketBeat 的数据，Rocket Pharmaceuticals 目前的共识评级为 “持有”，共识目标价为 21.21 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on RCKT</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 RCKT 股票分析</strong></p>
</div><h2>About Rocket Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Rocket Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.</p>
<div class="lb-trans"><p>Rocket Pharmaceuticals, Inc 及其子公司作为一家晚期生物技术公司，专注于开发针对罕见和严重疾病的基因疗法。它有三个临床阶段的外源性慢病毒载体项目，分别针对范可尼贫血（Fanconi anemia）、白细胞粘附缺陷-I（leukocyte adhesion deficiency-I）和丙酮酸激酶缺乏症（pyruvate kinase deficiency）。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Rocket Pharmaceuticals</li>
<li>How to Invest in Blue Chip Stocks</li>
<li>Near 52-Week Lows, These 3 Mid-Cap Stocks Are Worth a Look</li>
<li>What is Forex and How Does it Work?</li>
<li>3 Overlooked Dividend Plays for Income in Volatile Times</li>
<li>TSX Venture Exchange (Formerly Canadian Venture Exchange)</li>
<li>AXON: Competition Intensifies as Motorola Makes $4.4B Acquisition</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Rocket Pharmaceuticals</li>
<li>如何投资蓝筹股</li>
<li>接近 52 周低点，这 3 只中型股值得关注</li>
<li>外汇是什么，如何运作？</li>
<li>3 个被忽视的股息投资机会，适合波动时期</li>
<li>TSX 风险投资交易所（前身为加拿大风险投资交易所）</li>
<li>AXON：竞争加剧，摩托罗拉以 44 亿美元收购</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding RCKT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 RCKT 持有仓位的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - 免费报告) 的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkNLVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=RCKT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Rocket Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Rocket Pharmaceuticals 吗？</h2>
</div><p>Before you consider Rocket Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Rocket Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rocket Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Rocket Pharmaceuticals 并不在名单上。</p>
</div><p>While Rocket Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Rocket Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Sold by Bank of America Corp DE

- 美国银行在第四季度减少了对 Rocket Pharmaceuticals 的持股 44.8%。  
- 该公司目前持有 224,311 股，市值约 282 万美元。  
- 机构投资者和对冲基金持有该公司 98.39% 的股份。  

美国银行公司 DE 出售了 Rocket Pharmaceuticals, Inc.（纳斯达克股票代码：RCKT）的股份